Platinum Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Platinum Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-635,798	Closed	-$1.02M	–	149
2022 Q4	$1.02M	Sell	635,798 -593,747	-48%	-$878K	0.04%	96
2022 Q3	$1.78M	Hold	1,229,545	–	–	0.07%	81
2022 Q2	$2.25M	Buy	1,229,545 +249,460	+25%	+$478K	0.09%	79
2022 Q1	$2.62M	Hold	980,085	–	–	0.08%	74
2021 Q4	$4.24M	Sell	980,085 -98,018	-9%	-$574K	0.12%	69
2021 Q3	$5.49M	Hold	1,078,103	–	–	0.15%	60
2021 Q2	$6.82M	Buy	1,078,103 +292,204	+37%	+$2.28M	0.16%	56
2021 Q1	$6.08M	Buy	785,899 +482,434	+159%	+$3.82M	0.14%	50
2020 Q4	$1.99M	Buy	303,465 +103,241	+52%	+$738K	0.05%	91
2020 Q3	$1.33M	Buy	+200,224	New	+$1.48M	0.03%	98

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Platinum Investment Management's CTMX Position: Q1 2023 in Review

Platinum Investment Management sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 635,798 shares — an estimated $1.02M sold.

Platinum Investment Management first reported a position in CTMX in Q3 2020 and held it in 10 quarters. The position peaked at $6.82M in Q2 2021. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

Platinum Investment Management reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
Platinum Investment Management sold 635,798 CytomX Therapeutics shares in Q1 2023, an estimated $1.02M.
Platinum Investment Management first reported a position in CytomX Therapeutics in Q3 2020 and held it in 10 quarters.
Platinum Investment Management's CytomX Therapeutics position peaked at $6.82M in Q2 2021.
75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Platinum Investment Management's 13F filing for Q1 2023, filed 12 May 2023.